glp 1 and diabetic retinopathy Are GLP-1 receptor agonists foes or friends? A study in JAMA Network

The 2021 STEP 4 trial, published in JAMA, showed that people who continued semaglutide after an initial 20-week run-in kept losing weight, while those who switched to placebo regained nearly 7% of their body weight, confirming that ongoing treatment is key to maintaining results

Pennings provides expert insight into the mechanism of these new medications

La investigacin compara a pacientes con diabetes tipo 2 tratados con insulina con los que recibieron una clase de medicamentos agonistas de GLP-1, entre 2005 y 2018

Key points Taken once daily Improves blood sugar control Helps with moderate weight loss According to the Cleveland Clinic, liraglutide is effective, but daily injections can make long-term use harder for some patients

The ADA has released its 2023 guidelines